A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
Researchers identified a novel genetic risk factor for SARS-CoV-2 infection, linking a PTPN2 variant to increased ACE2 expression and susceptibility. The study suggests Tofacitinib may mitigate this risk, offering new treatment options for patients at higher genetic risk.
Cerebral vascular malformations (CVMs) are redefined as genetic and molecular-driven conditions, with innovative diagnostic approaches like next-generation sequencing and non-invasive imaging genomics. Targeted therapies, including MEK inhibitors and mTOR inhibitors, offer effective alternatives to traditional surgical methods.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
Researchers explore the role of efferocytosis in reducing inflammation and containing injury spread after an ischemic stroke. Efferocytosis may offer a promising therapeutic strategy to promote neural regeneration and minimize brain damage.
Researchers developed a computer model to predict which medication works best for each individual patient with CML. The approach has the potential to improve treatment outcomes for patients who previously relied on stem cell transplantation.
Researchers have identified a 177-gene signature common to metastasis across cancers, allowing for personalized risk assessment and potential therapies. The discovery could lead to broader treatment options, faster drug access, and improved patient outcomes.
Researchers developed a predictive tool using the Florey Dementia Index to forecast onset ages of mild cognitive impairment and Alzheimer's. The validated tool may help prioritize patients for disease-modifying treatments.
Researchers developed a gene therapy approach to treat chronic hypereosinophilia by delivering an anti-human eosinophil antibody via AAV-based gene therapy. The therapy successfully suppressed blood eosinophil levels in mice, showing promise as a potential treatment for the condition.
NRG Oncology has established a new Theranostics Subcommittee to develop a more robust theranostics program within its portfolio. The subcommittee will serve as a resource for research investigators and collaborate with other organizations to enhance the effects of treatment on targeted cancer.
The prevalence of substance use disorder surged during the COVID-19 pandemic, but treatment receipt declined initially due to healthcare disruptions. Treatment rates began to recover in 2022, likely driven by reopened treatment programs and increased telehealth use.
Researchers characterize the mysterious C-terminal domain of dystrophin and its role in stabilizing cellular membranes across various tissues. The study reveals that dystrophin's CT domain interacts differently with two major dystrobrevin isoforms, driving differences in binding affinity and interaction modes.
Researchers from Korea University have developed a groundbreaking technique to transform fibroblasts into mature cardiomyocytes, holding promise for regenerative medicine in treating cardiovascular disease. The method combines fibroblast growth factor 4 (FGF4) with vitamin C to accelerate cell maturation and enhance function.
Researchers at U of T have created SIMPL2, a platform that simplifies detection and improves accuracy of protein-protein interactions. The tool enables the rapid identification of protein interactions, including weak ones, for targeted drug therapies.
A groundbreaking study reveals lithium can restore brain function and alleviate behavioral symptoms in animal models of autism spectrum disorder caused by Dyrk1a gene mutations. Lithium normalizes brain size, restores neural structure and function, and improves social interaction and anxiety behaviors.
A clinical trial showed that an antibody blocking Nogo-A protein improves motor function in patients with incomplete spinal cord injuries. The treatment led to significant improvements in voluntary muscle activation and everyday life functional independence. Further studies are needed to confirm the findings.
A study led by Henry J. Pownall and Khurram Nasir found a strong link between the amount of free cholesterol in HDL and its accumulation in macrophages, which can contribute to heart disease. The researchers aim to develop new diagnostics and treatments for managing heart disease using HDL-free cholesterol as a biomarker.
Nearly 50 ISS National Lab-sponsored payloads splashed down safely on SpaceX’s CRS-31 mission, including research for early cancer detection and neurodegenerative conditions treatments. The investigations leveraged the space station's unique environment to improve life on Earth.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
The Keck School of Medicine of USC has joined the Ryght Research Network to leverage AI tools and optimize cancer clinical trials. The collaboration aims to offer more clinical trials to patients, build new AI tools, and speed up the development of medical treatments.
Engineered yeast cells can form cooperative groups that perform complex tasks and self-regulate in response to external signals. This approach enables precise production of therapeutic compounds, reducing waste and increasing treatment efficacy.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
The University of Surrey's research focuses on targeting mutated pathways with new drugs to treat rare conditions like immunodeficiencies. The team discovered that mTOR inhibitors can help restore normal B cell function.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
Lauren Averett Byers, a professor at MD Anderson Cancer Center, has received the 2025 Edith and Peter O'Donnell Award in Medicine from Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her fundamental discoveries in small cell lung cancer. Her work has led to personalized treatments and improved patient outcomes.
A new study reveals significant provincial and territorial variations in reimbursement criteria for cardiovascular medications in Canada. The current system leads to unequal access to evidence-based treatments, with the most vulnerable groups facing restricted access to life-saving medications.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
Researchers have developed an mRNA cure for pre-eclampsia using a lipid nanoparticle, reducing maternal blood pressure and improving fetal health. The therapy, tested in pregnant mice, has shown promising results and is poised to move forward to human trials.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Researchers have identified new potential therapeutic targets for diabetic kidney disease (DKD), a leading cause of kidney failure. The study reveals common and cell-type-specific changes caused by insulin-resistance, representing new targets for pharmacological or targeted gene therapy approaches.
Researchers found variation in practice patterns of sarcoidosis treatment, particularly in the use of nonsteroidal immunosuppressive medications and sequence of administration. The study highlights the need for future randomized trials and comparative effectiveness studies to ascertain optimal treatment algorithms.
Dr. Christopher Seet has received a $2.9 million R37 MERIT Award from the National Cancer Institute to develop innovative T cell therapies for cancer. The grant will support research into iPSC-derived T cells, which can be engineered for enhanced tumor-fighting capabilities.
Researchers identified the critical role of TIMM50 protein in mitochondrial energy production and its link to a severe and rare neurological disease. The study's findings suggest potential targets for future drug treatments and advance research on protein import into mitochondria in brain cells.
Dr. Aditya Bardia's appointment as Editor-in-Chief of Breast Cancer Research and Treatment reflects his expertise in targeted therapies and innovative research. He aims to foster innovation and disseminate knowledge benefiting patients and the scientific community through this journal.
A study found that psilocybin-assisted psychotherapy significantly reduced depression among clinicians providing front-line COVID-19 care. The treatment was more effective than a placebo, with participants experiencing greater reductions in symptoms over time.
Pusan National University researchers have identified genes that are overexpressed in peri-implantitis, a condition similar to periodontitis but with higher recurrence rates. The study's findings may help diagnose and treat the disease with targeted therapies.
Researchers have found that B7-H4 helps ACC tumors evade the immune system, leading to poor survival outcomes. A new drug targeting B7-H4 showed promising results in shrinking tumors in aggressive cases.
A new study found that gene therapy delandistrogene moxeparvovec significantly extended the median survival of Duchenne muscular dystrophy (DMD) rats to >25 months. Additionally, the treatment elicited statistically significant improvements in cardiac parameters and mobility.
A study found that postmenopausal women with low-risk tumors experience a long-term benefit from anti-hormonal treatment of at least 20 years, while younger women do not. The researchers highlight the need for new markers to predict long-term risk and benefit in younger patients.
A new review synthesizes evidence from molecular studies, animal research, and human trials to understand how ayahuasca influences emotional processing and memory systems. Key findings include ayahuasca's dual action through serotonin receptor types 5-HT2A and 5-HT1A.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
Researchers at Mass Eye and Ear developed an mRNA-based therapy to prevent scarring and blindness in PVR. The treatment, called RUNX1-Trap, targets a protein that regulates scar tissue formation, showing early promise for treating this eye disease.
The SONIA trial found that delaying and shortening CDK4/6 inhibitor treatment in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes while reducing toxicity and cost by €45 million per year. This innovative approach could reduce the burden on healthcare systems worldwide.
A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.
Researchers found impaired PD-1 activity can significantly reduce antibody diversity and quality in memory B cells. This may explain the increased rates of infection reported in patients with cancer receiving checkpoint inhibitor therapy.
Researchers at UCL found that excess brain volume loss with amyloid-targeting immunotherapies is associated with therapy effectiveness, not harm. The 'amyloid-removal-related pseudo-atrophy' or ARPA phenomenon suggests that removal of amyloid plaques may be the cause of observed brain changes.
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
The new effort aims to rapidly transform academic breakthroughs into life-saving therapies for a range of medical conditions. Autobahn Labs will invest up to $5 million per selected project to support the development of new pharmaceuticals.
Researchers explore adapting agricultural techniques, such as integrated pest management, to treat cancer. By managing cancer as a chronic condition, adaptive therapy aims to overcome treatment resistance and improve patient outcomes.
Researchers found that short-term MHT did not cause long-term cognitive decline in women in early postmenopause. The KEEPS Continuation Study suggests that timing is crucial for the safety of MHT.
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
Researchers developed a novel lentivirus-based gene therapy strategy in CD34+ hematopoietic progenitor cells, which showed therapeutic levels of expression of the anti-sickling beta globin protein. Cyclosporin improved transduction efficiency and preserved cell viability.
A new finger prick test for Alzheimer's disease has shown strong performance in a European study, measuring biomarkers in blood from superficial vessels. The test could soon be implemented globally, increasing accessibility to Alzheimer's testing without the need for high-sensitivity analyses.
Researchers found that sacubitril-valsartan, a commonly prescribed heart failure medication, can help prevent heart damage related to chemotherapy treatment among high-risk cancer patients. The study highlights the importance of identifying patients at high risk for heart damage and suggests strategies for early intervention.
A study reveals that nearly 137 million US adults are eligible for semaglutide therapy, more than the number eligible for statins. Semaglutide's broad eligibility could lead to increased adoption and treatment options for US adults.
A novel CAR T-cell therapy targeting p95HER2-expressing cells demonstrates complete and durable antitumor responses in a subset of HER2+ tumors, raising hopes for improved cancer treatment. The therapy also activates immune cells within the tumor microenvironment, showing promising results.
A study found that pharmacists who received feedback about their heart failure patients increased the frequency of their patient interactions and prescribed more medication adjustments. The intervention, which provided educational resources and monthly audit and feedback emails, led to a significant increase in heart failure management.
Researchers found that ablation reduced ICD shocks for ventricular tachycardia and episodes of VT not detected by the ICD. This minimally invasive procedure destroys abnormal heart tissue causing VT, offering a better alternative to long-term medication side effects.